This company has been acquired
ATRI Stock Overview
Develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Atrion Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$459.92 |
| 52 Week High | US$503.24 |
| 52 Week Low | US$274.98 |
| Beta | 0.69 |
| 1 Month Change | 0.62% |
| 3 Month Change | -0.88% |
| 1 Year Change | -3.11% |
| 3 Year Change | -35.22% |
| 5 Year Change | -40.14% |
| Change since IPO | 1,790.08% |
Recent News & Updates
Recent updates
There May Be Some Bright Spots In Atrion's (NASDAQ:ATRI) Earnings
May 22
Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading
Mar 24Subdued Growth No Barrier To Atrion Corporation (NASDAQ:ATRI) With Shares Advancing 25%
Mar 23Here's Why Atrion (NASDAQ:ATRI) Can Manage Its Debt Responsibly
Feb 09Atrion Corporation's (NASDAQ:ATRI) 26% Share Price Surge Not Quite Adding Up
Jan 04Atrion (NASDAQ:ATRI) Seems To Use Debt Quite Sensibly
Sep 14Atrion (NASDAQ:ATRI) Will Want To Turn Around Its Return Trends
Jul 18Be Wary Of Atrion (NASDAQ:ATRI) And Its Returns On Capital
Apr 19Atrion (NASDAQ:ATRI) May Have Issues Allocating Its Capital
Oct 18Atrion: Attractively Priced For Exposure To Defensive Healthcare
Sep 08Atrion's (NASDAQ:ATRI) Upcoming Dividend Will Be Larger Than Last Year's
Aug 27Atrion raises dividend 10.3% to $2.15/share
Aug 22Some Investors May Be Worried About Atrion's (NASDAQ:ATRI) Returns On Capital
Jul 18Atrion (NASDAQ:ATRI) Could Be Struggling To Allocate Capital
Jan 03Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95
Nov 18Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95
Sep 03Shareholder Returns
| ATRI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.1% | -0.9% | -1.2% |
| 1Y | -3.1% | 9.7% | 23.2% |
Return vs Industry: ATRI underperformed the US Medical Equipment industry which returned 9.8% over the past year.
Return vs Market: ATRI underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| ATRI volatility | |
|---|---|
| ATRI Average Weekly Movement | 1.6% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 19.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ATRI has not had significant price volatility in the past 3 months.
Volatility Over Time: ATRI's weekly volatility has decreased from 7% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 712 | David Battat | www.atrioncorp.com |
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company’s fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery.
Atrion Corporation Fundamentals Summary
| ATRI fundamental statistics | |
|---|---|
| Market cap | US$809.44m |
| Earnings (TTM) | US$12.56m |
| Revenue (TTM) | US$181.60m |
64.5x
P/E Ratio4.5x
P/S RatioIs ATRI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATRI income statement (TTM) | |
|---|---|
| Revenue | US$181.60m |
| Cost of Revenue | US$121.05m |
| Gross Profit | US$60.55m |
| Other Expenses | US$47.99m |
| Earnings | US$12.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.13 |
| Gross Margin | 33.34% |
| Net Profit Margin | 6.91% |
| Debt/Equity Ratio | 0% |
How did ATRI perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield123%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/21 02:09 |
| End of Day Share Price | 2024/08/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atrion Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Norbert Kalliwoda | Dr. Kalliwoda Research |
| Jayaprabha Dhavale | Virtua Research Inc. |